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The filamin family consists of three large di-
meric  proteins  (filamin  A  [FlnA],  FlnB,  and 
FlnC) that cross-link actin filaments, tether 
membrane glycoproteins, and serve as scaffolds 
for signaling intermediates (Stossel et al., 2001; 
Zhou et al., 2010). The most abundant isoform 
of the family, FlnA, is encoded by the X chro-
mosome in humans and mice (Feng and Walsh, 
2004; Robertson, 2005). FlnA is composed of 
an N-terminal actin-binding domain followed 
by 24 Ig repeats, the C-terminal of which me-
diates their dimerization (Pudas et al., 2005). 
Human  melanoma  cells  that  lack  FlnA  have 
poor motility and continuous membrane bleb-
bing (Cunningham et al., 1992; Flanagan et al., 
2001). FLNA mutations have been associated 
with periventricular heterotopia, Ehlers-Danlos 
Syndrome, or familial cardiac valvular dystrophy 
(Fox et al., 1998; Robertson et al., 2003; Sheen 
et al., 2005; Kyndt et al., 2007; Unger et al., 
2007). Loss of FlnA in mice results in embry-
onic lethality caused by pericardiac and visceral 
hemorrhage,  severe  cardiac  structural  defects, 
and aberrant vascular patterning (Feng et al., 
2006; Hart et al., 2006).
Platelets predominantly express FlnA (5 µM), 
although a small amount of FlnB is also expressed 
(<0.5 µM). Platelet FlnA has a critical structural 
role  in  attaching  the  Von  Willebrand  Factor 
(VWF)  receptor  complex  GPIb-IX-V  to  the 
underlying  actin  cytoskeleton.  aa  556–577  in 
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Filamin A (FlnA) cross-links actin filaments and connects the Von Willebrand factor recep-
tor GPIb-IX-V to the underlying cytoskeleton in platelets. Because FlnA deficiency is  
embryonic lethal, mice lacking FlnA in platelets were generated by breeding FlnAloxP/loxP 
females with GATA1-Cre males. FlnAloxP/y GATA1-Cre males have a macrothrombocytopenia 
and increased tail bleeding times. FlnA-null platelets have decreased expression and altered 
surface distribution of GPIb because they lack the normal cytoskeletal linkage of GPIb to 
underlying actin filaments. This results in 70% less platelet coverage on collagen-coated 
surfaces at shear rates of 1,500/s, compared with wild-type platelets. Unexpectedly,  
however, immunoreceptor tyrosine-based activation motif (ITAM)- and ITAM-like–mediated 
signals are severely compromised in FlnA-null platelets. FlnA-null platelets fail to spread 
and have decreased -granule secretion, integrin IIb3 activation, and protein tyrosine 
phosphorylation, particularly that of the protein tyrosine kinase Syk and phospholipase  
C–2, in response to stimulation through the collagen receptor GPVI and the C-type  
lectin-like receptor 2. This signaling defect was traced to the loss of a novel FlnA–Syk 
interaction, as Syk binds to FlnA at immunoglobulin-like repeat 5. Our findings reveal that 
the interaction between FlnA and Syk regulates ITAM- and ITAM-like–containing receptor 
signaling and platelet function.
© 2010 Falet et al.  This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months after 
the publication date (see http://www.rupress.org/terms). After six months it is 
available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
by-nc-sa/3.0/).
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In this study the role of FlnA was probed in platelets. Mouse 
platelets lacking FlnA were generated by breeding FlnAloxP/loxP 
females with GATA1-Cre males (Jasinski et al., 2001). Off-
spring  FlnAloxP/y  GATA1-Cre  males  have  <15%  of  normal 
blood platelet count, and their platelets lack FlnA. As expected, 
FlnA-null platelets are large, lack normal actin-GPIb mem-
brane attachments, and have an altered distribution of GPIb 
on their surface. However, FlnA-null platelets surprisingly also 
have severe functional impairment in signaling responses down-
stream of the immunoreceptor tyrosine-based activation motif 
(ITAM)– and ITAM-like–mediated signal receptors GPVI and 
C-type lectin-like receptor 2 (CLEC-2). This specific signaling 
defect results from the loss of a novel and direct FlnA–Syk in-
teraction mediated through Ig repeat 5 of FlnA. As a conse-
quence, Syk is mistargeted in FlnA-null platelets, and ITAM 
signaling that normally leads to actin assembly, -granule secre-
tion, integrin IIb3 activation, and protein tyrosine phos-
phorylation is interrupted. FlnA is, therefore, required for 
normal ITAM- and ITAM-like–based signaling responses.
RESULTS
Mild thrombocytopenia in female mice carriers  
for FlnA deficiency
FlnA deficiency in mice results in lethality in utero as a result of 
pericardiac and visceral hemorrhage, severe cardiac structural 
the  cytoplasmic  tail  of  GPIb  constitutively  interacts  with 
FlnA Ig repeat 17 (Nakamura et al., 2006), and the loss of 
GPIb in mice results in enlarged platelets, a phenotype which 
can be rescued by expression of a chimeric protein construct 
containing the cytoplasmic domain of human GPIb (Ware   
et al., 2000; Kanaji et al., 2002). FlnA binding facilitates GPIb 
surface expression in Chinese hamster ovary (CHO) cells (Feng 
et al., 2005), and the interaction between FlnA and GPIb has 
been reported to influence VWF receptor function, although 
conflicting effects are found in the literature. CHO cells trans-
fected with GPIb mutants that lack the FlnA binding site 
have decreased VWF binding (Dong et al., 1997; Schade et al., 
2003), VWF-induced cell aggregation (Mistry et al., 2000), 
and/or adhesion to a VWF matrix under high shear (Cranmer 
et al., 1999; Williamson et al., 2002; Cranmer et al., 2005).   
In contrast, another study has shown that FlnA binding to 
GPIb negatively regulates VWF binding to CHO cells and 
CHO cell adhesion under both static and flow conditions   
(Englund et al., 2001). Platelets treated with cell-permeable 
peptide mimics of the FlnA binding site on GPIb have de-
creased ability to activate their fibrinogen receptor, the integ-
rin IIb3, and change shape in response to VWF stimulation, 
suggesting that the interaction between FlnA and GPIb posi-
tively modulates signaling events initiated by VWF in platelets 
(Feng et al., 2003; David et al., 2006).
Figure 1.  FlnA/B expression in platelets and mouse tail bleeding time. (A–C) FlnA expression in FlnA+/+ (A), FlnA+/ (B), and FlnAloxP/y GATA1-Cre  
(C) platelets was evaluated by intracellular flow cytometry using a rabbit antibody directed against mouse FlnA (thin line). A nonspecific rabbit antibody 
was used as a control (gray area). (D) Lysates corresponding to 5 × 106 FlnA+/y GATA1-Cre and FlnAloxP/y GATA1-Cre platelets were subjected to SDS-PAGE 
and probed with anti-FlnA antibody, as indicated. FlnB expression in FlnA+/y GATA1-Cre (E) and FlnAloxP/y GATA1-Cre (F) platelets was evaluated by intra-
cellular flow cytometry using a rabbit antibody directed against human FlnB (thin line). A nonspecific rabbit antibody was used as a control (gray area). 
Results are representative of five independent experiments. (G) FlnA+/y GATA1-Cre (n = 16) and FlnAloxP/y GATA1-Cre (n = 16) mouse tail bleeding times 
were statistically analyzed by the Kaplan-Meier method. FlnA+/y GATA1-Cre mice show a median bleeding time of 165 s. FlnAloxP/y GATA1-Cre mice  
displayed a severe bleeding phenotype, with 13 of 16 (81%) mice having bleeding times that exceeded 600 s (log-rank p = 1.27 × 107).JEM VOL. 207, August 30, 2010 
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complex  developmental  abnormalities  (unpublished  data), 
which  is  consistent  with  leaky  GATA1-Cre  expression  in 
early embryogenesis leading to FlnAloxP gene recombination 
in multiple nonhematopoietic tissues (Mao et al., 1999; Jasinski 
et al., 2001).
Macrothrombocytopenia in male mice with platelets  
lacking FlnA
Blood counts revealed a macrothrombocytopenia in 6–8-
wk-old FlnAloxP/y GATA1-Cre males (Table II). The mean 
blood platelet count was 284 ± 70 × 103/µl (n = 16), com-
pared with 1,773 ± 403 × 103/µl (n = 19; P < 0.001) in 
control FlnA+/y GATA1-Cre males, an 84% reduction. The 
mean volume of FlnA-null platelets was 13.2 ± 2.1 fl, com-
pared with 6.3 ± 0.5 fl in control males (P < 0.001). FlnAloxP/y 
GATA1-Cre males had increased lymphocyte count com-
pared with FlnA+/y GATA1-Cre males. Other blood cell 
parameters were in the normal range. The 2.1-fold in-
creased platelet volume correlated with a 2.7-fold increase 
in total protein content, from 927 ± 95 fg per FlnA-expressing 
platelet (n = 6) to 2,464 ± 263 fg per FlnA-null platelet (n = 9; 
P < 0.0001), as determined by Bradford assay using BSA   
as standard.
FlnA expression was evaluated in platelets isolated from 
FlnA+/y GATA1-Cre and FlnAloxP/y GATA1-Cre males by 
intracellular flow cytometry (Fig. 1 C) and by SDS-PAGE 
and immunoblotting (Fig. 1 D). FlnA expression was absent 
in most platelets isolated from FlnAloxP/y GATA1-Cre males. 
A small population (<5%) of FlnA-containing platelets could 
be detected in some animals, suggesting mosaic GATA1- 
Cre expression, rendering incomplete FlnAloxP excision. In 
contrast, FlnB expression levels appeared to be increased by 
approximately twofold in FlnA-null platelets, compared with 
WT (Fig. 1, E and F).
defects, and aberrant vascular patterning (Feng et al., 2006; Hart 
et al., 2006). Because the FLNA gene is located on the X chro-
mosome, we determined whether it conferred survival value   
to platelets in 6–8-wk-old heterozygous female mice carrying 
both one WT and one deleted FLNA gene. FlnA+/ females 
had a mild thrombocytopenia (Table I). Their blood platelet 
count was 678 ± 278 × 103/µl (mean ± SD; n = 14), compared 
with 994 ± 294 × 103/µl (n = 17; P < 0.01) in WT female lit-
termates, revealing a reduction of 32%. The mean platelet vol-
ume was increased by 8%, compared with WT female littermates 
(P < 0.05). FlnA+/ females also had increased leukocyte count, 
notably lymphocytes and granulocytes. Erythrocyte counts 
were normal.
Platelets were isolated from FlnA+/ and WT mouse blood, 
fixed and permeabilized, and FlnA expression was determined 
by intracellular flow cytometry using a rabbit antibody directed 
against FlnA hinge 1 (Fig. 1, A and B). Two populations, one 
positive and one negative, were identified in FlnA+/ females, 
compared with only one single FlnA-positive population in 
WT female littermates. 95 ± 2% (mean ± SD; n = 14) of plate-
lets isolated from FlnA+/ females contained FlnA, which was 
significantly greater than the expected 50% (P < 0.0001). 
FlnA-null platelets were large, as indicated by forward and side 
scatter dot plot analysis (unpublished data).
Generation of mice carrying platelets that selectively lack FlnA
GATA1-Cre transgenic mice were used to excise the FlnAloxP 
gene in the erythroid/megakaryocytic lineage (Jasinski et al., 
2001). FlnAloxP/loxP females were bred with GATA1-Cre males. 
In this cross, all offspring expressed GATA1-Cre, and females 
were heterozygous and males hemizygous for FlnAloxP. Only 
79 (14.2%) out of the 555 offspring obtained were males. 
Analysis of embryos collected at different stages of develop-
ment showed a high embryonic mortality associated with 
Table I.  Complete blood count in 6–8-wk-old FlnA+/+ and FlnA+/ female mice
Parameter FlnA+/+ (n = 17) FlnA+/ (n = 14) P-value
Erythrocytes 8,934 ± 2297 8,923 ± 2565 NS
Lymphocytes 4.46 ± 1.43 6.28 ± 2.16 <0.01
Granulocytes 0.30 ± 0.11 0.50 ± 0.24 <0.01
Platelets 994 ± 294 678 ± 278 <0.01
Mean platelet volume (fl) 6.3 ± 0.2 6.8 ± 0.9 <0.05
Results are expressed as mean × 103 cells/µl ± SD. NS indicates not significant.
Table II.  Complete blood count in 6–8-wk-old FlnA+/y GATA1-Cre and FlnAloxP/y GATA1-Cre male mice
Parameter FlnA+/y (n = 19) FlnAloxP/y (n = 16) P-value
Erythrocytes 8,648 ± 1596 8,753 ± 2234 NS
Lymphocytes 4.55 ± 2.17 7.71 ± 2.26 <0.05
Granulocytes 0.93 ± 0.66 0.74 ± 0.34 NS
Platelets 1773 ± 403 284 ± 70 <0.001
Mean platelet volume (fl) 6.3 ± 0.5 13.2 ± 2.1 <0.001
Results are expressed as mean × 103 cells/µl ± SD. NS indicates not significant.1970 FlnA regulates platelet signaling and function | Falet et al.
measurement point. In contrast, the median tail bleeding time 
for FlnA+/y GATA1-Cre males was 165 s (n = 16; log-rank   
P = 1.27 × 107).
Structure of platelets lacking FlnA
Loss of the GPIb–FlnA interaction alters the morphology of 
the resting platelet and its underlying cytoskeleton. Platelets 
isolated from FlnAloxp/y GATA1-Cre male mice are large but 
discoid, 4.0 µm in diameter at their longest axis, compared 
with 2.5 µm in controls. Fig. 2 (A and B) shows representa-
tive electron micrographs of the cytoskeletons of FlnA-null 
platelets prepared by removing the plasma membrane in the 
absence of glutaraldehyde with Triton X-100 detergent.   
In the absence of fixative, the bulk of the filaments composing 
the cytoskeleton are lost. In other words, cytoskeletal integrity 
is diminished as the bulk of the F-actin, but not the micro-
tubule ring, rapidly dissociates from the cytoskeleton when 
FlnA-null platelets are permeabilized in buffers that normally 
stabilize an intact F-actin cytoskeleton. The percentage of 
Increased tail bleeding time in mice with platelets lacking FlnA
FlnAloxP/y  GATA1-Cre  males  had  prolonged  tail  bleeding 
times (Fig. 1 G). 13 (81%) out of 16 FlnAloxP/y GATA1-Cre 
males had tail bleeding >10 min, which was our selected end 
Figure 2.  Role of FlnA expression in platelet morphology.  
(A and B) Representative cytoskeleton from a control FlnA+/y GATA1-Cre 
(A) or a FlnAloxP/y GATA1-Cre (B) resting platelet. Resting platelet cytoskeletons 
were prepared for the electron microscope by attachment to polylysine-
coated coverslips in a permeabilizing PHEM buffer containing 0.75% Tri-
ton X-100, followed by fixation with 1% glutaraldehyde, and freezing in 
water, freeze drying, and metal casting. The FlnA-null cytoskeleton is en-
larged and has a marginal microtubule ring, but the bulk of the cytoplas-
mic F-actin dissociates because of insufficient cross-linking of the actin 
filaments in the absence of FlnA. Bars, 0.2 µm. (C and D) Structure of the 
active cytoskeleton. FlnA+/y GATA1-Cre platelets (C) or FlnAloxP/y GATA1-Cre 
(D) were adhered to CRP-coated coverslips by centrifugation and incu-
bated for 10 min at 37°C. Cells were then permeabilized in Triton X-100 in 
PHEM buffer containing 0.01% glutaraldehyde and processed for the 
electron microscopy as described. Bars, 0.5 µm. (Insets) Platelets were 
attached to and incubated on CRP-coated coverslips as in C and D and 
fixed with 3.7% formaldehyde in PBS for 30 min. F-actin was stained 
using 0.1% Triton X-100 in PBS and 0.1 µm Alexa Fluor 568 phalloidin. 
Bars, 5 µm. (E and F) Actin assembly. FlnA+/y GATA1-Cre and FlnAloxP/y 
GATA1-Cre platelets were activated with various concentrations of 
thrombin (E) or CRP (F) for 2 min at 37°C, as indicated. Platelets were 
fixed and permeabilized, washed, incubated with TRITC-labeled phalloidin, 
and analyzed by flow cytometry. Results are the ratio between the mean 
fluorescence of activated versus resting platelets and represent the  
mean ± SE of four independent experiments.
Figure 3.  VWF receptor distribution in FlnA-null platelets.  
(A) GPIb is not linked to the cytoskeleton of FlnA-null platelets. FlnA+/y 
GATA1-Cre and FlnAloxP/y GATA1-Cre platelets were activated or not (Rest) 
with 0.5 U/ml thrombin (Thr) or 3 µg/ml CRP for 5 min, as indicated.  
Triton X-100 soluble (Sup) and insoluble (Pel) fractions were collected by 
centrifugation of platelet lysates at 100,000 g for 30 min at 4°C, subjected 
to SDS-PAGE, and probed with a rat anti-GPIb antibody. Results are 
representative of three independent experiments. (B) Distribution of anti-
GPIb gold on the surface of FlnA+/y GATA1-Cre and FlnAloxP/y GATA1-Cre 
platelets. GPIb is found in linear arrays on the WT platelet surface.  
Arrays are highlighted with yellow shading. Particle counts revealed that 
74.9 ± 5.9% of the total surface gold are in linear arrays composed of 
three or more particles. Only 13.1 ± 6.0% of the gold was arrayed on the 
FlnA-null platelet surface. Results are representative of five independent 
platelets for each mouse (0.5-µm2 area on each).JEM VOL. 207, August 30, 2010 
Article
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GPIb expression and distribution in FlnA-null platelets
Expression of major platelet surface glycoproteins on FlnA-
null platelets was examined by flow cytometry (Table III). 
FlnA deficiency resulted in a diminution of the expression of 
the VWF receptor, the GPIb-IX-V complex. Expression of 
the GPIb (CD42b) subunit was reduced by 45% and that   
of GPIb (CD42c), GPV (CD42d), and GPIX (CD42a) by   
25–30%. In contrast, expression of the fibrinogen receptor 
subunit, the integrin 3 (GPIIIa and CD41), and the collagen 
receptor GPVI was increased by 230 and 40%, respectively.
To demonstrate that the loss of FlnA results in untethered 
VWF complexes, the attachment of GPIb to the actin cyto-
skeleton of FlnA-null platelets was evaluated (Fig. 3 A). FlnA+/y 
GATA1-Cre and FlnAloxP/y GATA1-Cre platelets were lysed 
in PHEM buffer containing Triton X-100, and F-actin was 
collected by centrifugation at 100,000 g for 30 min (Falet   
et al., 2002). We found that 41 ± 4% of total GPIb was   
recovered in the Triton X-100–insoluble fraction of rest-
ing FlnA-positive platelets, which is consistent with earlier 
actin assembled into filaments was, however, comparable in 
the FlnA-null and WT platelets, representing 40% of the total 
actin levels. Because FlnA-null platelets are larger, they con-
tain more total actin filaments than the control cells.
FlnA-null platelets adhere to the collagen-related peptide 
(CRP)–coated surfaces, which are specific for the collagen re-
ceptor GPVI but spread poorly, and have one or more unusual 
F-actin enriched foci within their cytoplasm (Fig. 2, C and D). 
In the electron microscope, these foci are aggregates of mem-
brane skeleton and F-actin. In contrast, WT platelets activate on 
CRP-coated surfaces, spread, and generate blunt filopodia that 
are enriched in newly assembled F-actin, as indicated by both 
Alexa-phalloidin staining of F-actin and electron microscopy.
Fig. 2 (E and F) also shows that the limited shape change re-
action of FlnA-null platelets to CRP results from a blunted actin 
assembly process. Although the F-actin assembly response medi-
ated by the G protein–coupled receptor (GPCR) agonist throm-
bin is normal, FlnA-null platelets mount only a modest shape 
change and actin assembly reaction after CRP ligation of GPVI.
Table III.  Expression of major surface glycoproteins on FlnA-null platelets
Platelet glycoprotein FlnA+/y FlnAloxP/y P-value
GPIb (CD42b) 62.6 ± 3.2 34.2 ± 3.7 <0.005
GPIb (CD42c) 330.7 ± 43.2 251.1 ± 5.9 <0.05
GPIX (CD42a) 37.0 ± 6.3 27.8 ± 1.9 NS
GPV (CD42d) 67.3 ± 10.7 46.8 ± 4.1 NS
GPIIIa (CD61, integrin 3) 45.9 ± 17.1 152.4 ± 16.5 <0.005
GPVI 12.8 ± 2.8 17.9 ± 1.4 <0.05
The binding of fluorescently labeled antibodies directed against the platelet glycoproteins indicated above was measured by flow cytometry. Data are expressed as mean 
fluorescence intensity bound to the surface of FlnA+/y GATA1-Cre and FlnAloxP/y GATA1-Cre platelets and represent mean ± SD (n = 4-5 for each independent group).  
NS indicates not significant.
Figure 4.  Platelet adhesion to collagen-bound VWF under arterial shear conditions. (A) After 3 min of perfusion of identical concentrations  
of labeled platelets in whole blood over collagen-coated surfaces at 1,500/s, 20% of the surface was covered by FlnA+/y GATA1-Cre platelets. Bar, 50 µm. 
(B) Mean of FlnA+/y GATA1-Cre platelets was set to 100% for better comparability. FlnAloxP/y GATA1-Cre platelet fluorescence covered 70% less area than 
FlnA+/y GATA1-Cre platelets. Error bars represent mean ± SEM (n = 6 mice). (C) Dwell time of 60 individual platelets per group under the same experimen-
tal conditions was significantly shorter in FlnAloxP/y than in FlnA+/y GATA1-Cre platelets. One-fifth of FlnA-null platelets detached after <500 ms under 
arterial shear conditions, whereas all FlnA+/y GATA1-Cre platelets dwelled for >500 ms. Results are representative of three independent experiments.1972 FlnA regulates platelet signaling and function | Falet et al.
To test the hypothesis that the GPIb defect might result 
from a decreased stability of ligand binding rather than a 
decreased initial binding efficiency, we analyzed individual 
platelet binding to the coated surface with high temporal res-
olution under the same experimental conditions (Fig. 4 C). 
After  initial  tethering,  FlnA-null  platelets  showed  signifi-
cantly less firm adhesion than WT platelets. Although all WT 
platelets dwelled for at least 500 ms on the surface and 62% 
adhered firmly during the observation period, 23% of the 
FlnA-null platelets detached after <500 ms.
ITAM and ITAM-like signaling defects in FlnA-null platelets
The significance of FlnA expression in platelet responses to 
soluble agonists was tested (Fig. 5). Platelets isolated from 
FlnA+/y GATA1-Cre or FlnAloxP/y GATA1-Cre males were 
treated with GPCR agonists (i.e., ADP, the thromboxane 
analogue U46619, and/or epinephrine) and analyzed by flow 
cytometry using the antibody JON/A, which is specific for 
active IIb3 (Fig. 5 A). ADP induced comparable IIb3 
activation in WT and FlnA-null platelets alone or in combina-
tion with U46619, epinephrine, or both. Furthermore, U46619 
induced similar actin assembly responses in WT and FlnA-
null platelets (unpublished data).
accounts of 50% of GPIb associated with the resting cyto-
skeleton (Fox, 1985a,b). In contrast, all GPIb remained 
Triton X-100 soluble in FlnAloxP/y GATA1-Cre platelets. The 
lack of a cytoskeletal linkage altered the VWF receptor topol-
ogy such that it was dispersed randomly across the platelet sur-
face (Fig. 3 B). Particle counts revealed that only 10.6 ± 3.4% 
of GPIb was arrayed into linear rows in FlnA-null platelets, 
compared with 72.0 ± 6.2% in WT controls (5 µm2 area; n = 5), 
as described previously (Hoffmeister et al., 2003).
Platelet adhesion under arterial shear condition
The  functionality  of  FlnAloxP/y  GATA1-Cre  platelets  was 
tested in flow chamber experiments. Binding to a collagen-
coated surface was measured in whole blood after labeling of 
platelets and normalization of platelet counts. Perfusion was 
performed under arterial shear condition (shear rate 1,500/s), 
which mediates binding of plasma VWF to surface-bound 
collagen (Ruggeri and Mendolicchio, 2007; Diener et al., 
2009). Fluorescent FlnA-null platelets covered 70% less of 
the collagen-coated surface than did WT platelets (Fig. 4,   
A and B). Considering that FlnA-null platelets are larger in 
size than WT platelets, this reveals a highly significant defect 
in binding to collagen-coated surface under arterial shear.
Figure 5.  Functional defects in FlnA-null platelets. (A) FlnA+/y GATA1-Cre and FlnAloxP/y GATA1-Cre platelets in platelet-rich plasma (PRP) were acti-
vated with 10 µM ADP, 10 µM U46619, and/or 10 µM epinephrine (Epi), as indicated, and directly stained with PE-labeled JON/A for 10 min at room tem-
perature. Platelets were then analyzed by flow cytometry. Results are the ratio between the mean fluorescence of activated versus resting platelets and 
represent the mean ± SD of four independent experiments. FlnA+/y GATA1-Cre and FlnAloxP/y GATA1-Cre platelets were activated with 50 nM PMA (B and G) or 
various concentrations of thrombin (C and H), CRP (D and I), convulxin (E and J), or rhodocytin (F and K) for 2 min at 37°C, as indicated. Platelets were 
then incubated with an FITC-labeled anti–mouse P-selectin antibody (B–F) or with Oregon green 488–labeled fibrinogen (G–K) and analyzed by flow  
cytometry. Results are expressed as percentage of positive platelets and represent mean ± SE of four independent experiments.JEM VOL. 207, August 30, 2010 
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that signals coming from CLEC-2 that lead to P-selectin ex-
pression and integrin IIb3 activation were also highly di-
minished in FlnA-null platelets, in a similar fashion to those 
coming from GPVI.
Impaired tyrosine phosphorylation in FlnA-null platelets
The data described in the previous section suggest that FlnA 
modulates platelet signaling downstream of ITAM- and ITAM-
like–containing receptors (i.e., GPVI and CLEC-2), cascades 
initiated by tyrosine phosphorylation, and activation of signal-
ing proteins that include the protein tyrosine kinase Syk and 
phospholipase C-2 (PLC-2; Watson et al., 2005; Suzuki- 
Inoue et al., 2006). Hence, the ability of FlnA-null platelets to 
phosphorylate proteins on tyrosine in response to CRP, con-
vulxin, or rhodocytin was investigated (Fig. 6). In FlnA+/y 
GATA1-Cre platelets, CRP, convulxin, and rhodocytin in-
duced tyrosine phosphorylation of numerous platelet proteins, 
including a 130-kD protein that comigrates with PLC-2. The 
profile of tyrosine phosphorylation was markedly reduced in 
FlnAloxP/y GATA1-Cre platelets stimulated in the same condi-
tions. Immunoprecipitation confirmed that Syk and PLC-2 
phosphorylation was severely compromised in these platelets, 
thus revealing an important early role for FlnA in the ITAM- 
and ITAM-like–mediated signaling cascades (Fig. 6).
FlnA associates with Syk
Because the block in ITAM-based signaling in platelets oc-
curs early, as judged by the decreased phosphorylation of Syk 
and PLC-2, we investigated whether FlnA interacts with 
any signaling molecules involved in the GPVI and CLEC-2 
signaling pathways and found that FlnA directly binds to Syk. 
Syk immunoprecipitates were prepared from human platelet 
lysates and were probed against FlnA (Fig. 7 A). FlnA associ-
ated with immunoprecipitated Syk in both resting and CRP-
activated platelets.
The  secretory  and  aggregatory  capacities  of  FlnA-null 
platelets were further tested. WT and FlnA-null platelets 
were treated with PMA, which activates protein kinase C di-
rectly, and analyzed by flow cytometry for P-selectin (CD62P) 
expression, as a marker for -granule secretion, or fibrinogen 
binding, as a marker for integrin IIb3 activation (Falet et al., 
2009). FlnA-null platelets expressed P-selectin and bound fibri-
nogen normally in response to PMA (Fig. 5, B and G).
Platelets isolated from FlnA+/y GATA1-Cre or FlnAloxP/y 
GATA1-Cre males were also treated with the GPCR agonist 
thrombin. Thrombin induced a concentration-dependent   
increase of P-selectin expression and fibrinogen binding   
in FlnA+/y GATA1-Cre platelets, reaching 93.1 ± 0.5% of   
P-selectin–expressing and 82.8 ± 6.9% of fibrinogen-binding 
platelets with 0.5 U/ml thrombin (Fig. 5, C and H). FlnA 
deficiency resulted in a significant decrease of platelet re-
sponses to thrombin, as only 55.9 ± 2.2% of P-selectin– 
expressing and 65.6 ± 5.9% of fibrinogen-binding platelets 
were obtained with 0.5 U/ml of thrombin.
Responses to CRP and convulxin, which are both specific 
for the collagen receptor GPVI (Watson et al., 2005), were   
severely affected by FlnA deficiency (Fig. 5, D, E, I, and J). 
Only 32.7 ± 6.7% of CD62P-expressing and 32.5 ± 6.6% of 
fibrinogen-binding FlnAloxP/y GATA1-Cre platelets were ob-
tained with 10 µg/ml CRP, compared with 80.0 ± 6.2 and 
72.5 ± 6.9% of FlnA+/y GATA1-Cre platelets, respectively. 
Similarly, only 42.6 ± 1.1% of P-selectin–expressing and 18.0 ± 
4.8% of fibrinogen-binding FlnAloxP/y GATA1-Cre platelets 
were obtained with 200 ng/ml convulxin, compared with 
82.8 ± 1.5% of P-selectin–expressing and 47.2 ± 2.3% of 
fibrinogen-binding FlnA+/y GATA1-Cre platelets, respectively.
To determine if the poor response to GPVI is extended 
to ITAM-like signaling, we assessed the ability of rhodocytin 
to  activate  WT  and  FlnA-null  platelets  through  CLEC-2 
(Suzuki-Inoue et al., 2006; Fig. 5, F and K). The data reveal 
Figure 6.  Protein tyrosine phosphorylation in platelets. FlnA+/y GATA1-Cre and FlnAloxP/y GATA1-Cre platelets were activated with CRP (A), convulxin 
(B), or rhodocytin (C) for 2 min at 37°C as indicated. Platelet lysates and Syk and PLC-2 were subjected to SDS-PAGE and probed with anti-Syk, anti-
PLC-2, and anti-phosphotyrosine antibodies as indicated. Results are representative of three independent experiments.1974 FlnA regulates platelet signaling and function | Falet et al.
The localization of Syk in WT and FlnA-null platelets was 
analyzed after adherence to CRP-coated surfaces. Fig. 7 B shows 
WT and FlnA-null platelets on CRP-coated surfaces after 
staining with rabbit anti-Syk antibody BR15 and Alexa Fluor 
488–conjugated phalloidin and TRITC-labeled goat anti–
rabbit IgG. Syk appears to be associated with the membrane in 
WT platelets and more cytoplasmic in FlnA-null platelets, indi-
cating that FlnA contributes to Syk spatial distribution to the 
cytoplasmic surface of the platelet plasma membrane.
The FlnA–Syk interaction was further investigated in vitro 
using recombinant proteins. His-tagged FlnA constructs con-
taining repeats 1–8+24, 8–15+24, or 16–24 were incubated 
with a fusion protein containing GST-Syk. The construct con-
taining FlnA repeats 1–8+24 was pulled down by GST-Syk, 
but not GST alone, as indicated by anti-His immunoblotting 
(Fig. 7 C). Binding to repeats 8–15+24 and 16–24 was not de-
tected, indicating that Syk binds to the FlnA N-terminal region 
containing repeats 1–8. We further determined that Syk bind-
ing occurs to FlnA repeat 5 (Fig. 7 D), as GST-His-Syk pre-
dominantly pulled down eGFP-tagged FlnA repeat 5. Weak 
binding to repeats 1–3, 4, and 6–7, but not to FlnA actin-binding 
domain and repeat 8, was also observed.
DISCUSSION
Our  results  show  that  FlnAloxP/y  GATA1-Cre  males  have 
<15% of normal blood platelet count and increased tail bleed-
ing time. These mice have enlarged platelets that lack FlnA. 
FlnA-null platelets lack normal actin membrane attachments 
and have decreased and altered GPIb expression on their 
surface and impaired adhesion to collagen under flow con-
ditions. Unexpectedly, FlnA-null platelets also have severe 
functional and signaling impairment in response to stimula-
tion through ITAM- and ITAM-like–mediated signal recep-
tors GPVI and CLEC-2, signaling which requires activation 
Figure 7.  Syk associates with FlnA Ig repeat 5. (A) FlnA and Syk associate in platelets. Human platelets were activated, or not, with 3 µg/ml CRP for  
2 min at 37°C. Syk and FlnA were immunoprecipitated with rabbit antibodies N19 and 4762, respectively. Immunoprecipitates were subjected to SDS-PAGE 
and probed for FlnA. A control rabbit IgG was used as negative control for specificity. Results are representative of two experiments. (B) FlnA restricts Syk to 
the periphery of spread platelets. FlnA+/y GATA1-Cre and FlnAloxP/y GATA1-Cre platelets were attached by centrifugation at 280 g for 5 min on CRP-coated 
coverslips, incubated by 5 min at 37°C, fixed with 3.7% formaldehyde for 20 min, permeabilized with 0.1% Triton in 1% BSA/PBS, and incubated with anti-
Syk antibody BR15 followed by a secondary Alexa Fluor 488–conjugated anti–rabbit Ig antibody in PBS/1% BSA containing 0.1 µM rhodamine-phalloidin. 
Bar, 5 µm. Results are representative of two experiments. (C) 100 nM His-tagged FlnA recombinant truncates containing Ig repeats 1–8+24, 8–16+24, or 
17–24 were incubated with 25 nM GST-Syk or GST alone as control. Complexes were pulled down with glutathione Sepharose beads, subjected to SDS-
PAGE, and probed for His (FlnA) as indicated. Results are representative of four experiments. (D) 50 nM eGFP-tagged FlnA repeat fragments containing full-
length FlnA (FL), its actin-binding domain (ABD), or Ig repeats 1–3, 4, 5, 6–7, or 8 were incubated with 500 nM GST-Syk. Complexes were pulled down with 
glutathione Sepharose beads, subjected to SDS-PAGE, and probed for eGFP (FlnA). Results are representative of four experiments.
of the protein tyrosine kinase Syk. Interaction between plate-
let FlnA and Syk was detected by immunoprecipitation and 
reconstituted using purified proteins.
Because FlnA deficiency is embryonic lethal in mice (Feng 
et al., 2006; Hart et al., 2006), mice lacking FlnA in platelets 
were generated using the Cre–loxP system. FlnAloxP/loxP fe-
male mice were bred with erythroid/megakaryocytic-specific 
GATA1-Cre transgenic male mice. In agreement with the in-
activation of the PIGA gene (Jasinski et al., 2001), we found 
that GATA1-Cre caused high efficiency FLNA gene inactiva-
tion in mouse megakaryocytes, as FlnA expression was absent 
in most platelets isolated from FlnAloxP/y GATA1-Cre male 
mice. A small population (<5%) of FlnA-containing platelets 
could be detected in some animals, suggesting mosaic GATA1-
Cre expression, rendering incomplete FlnAloxP excision. 
Whether these platelets contain full-length FlnA or a trun-
cated form, as shown for talin (Priddle et al., 1998), remains to 
be investigated. The high efficiency of gene inactivation is 
similar to that described for the widely used megakaryocyte-
specific Pf4-Cre transgenic mouse and posits the GATA1-Cre 
mouse as a strong alternative for studies in megakaryocytes and 
platelets (Léon et al., 2007; Petrich et al., 2007; Tiedt et al., 
2007; Hitchcock et al., 2008; Wen et al., 2009).
FlnA deficiency in FlnAloxP GATA1-Cre mice was associ-
ated with a high embryonic mortality, as our breeding strategy 
resulted  in  only  14.2%  of  pups  being  hemizygous  FlnA- 
deficient males, which was lower than the expected 50%. 
GATA1-Cre is turned on early in embryogenesis and is also ex-
pressed outside of the hematopoietic system (Mao et al., 1999; 
Jasinski et al., 2001). Analysis of embryos collected at differ-
ent stages of development showed complex developmental 
abnormalities, which is consistent with leaky Cre expression in 
early embryogenesis leading to FlnAloxP gene recombination in 
multiple nonhematopoietic tissues. The FlnAloxP/y GATA1-Cre JEM VOL. 207, August 30, 2010 
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the importance of this interaction to platelet tethering under 
arterial shear conditions. Diminished binding to collagen and 
collagen-associated VWF and poor adherence under flow 
could result from the decreased density of GPIb on the sur-
face of FlnA-null platelets or from its changed topology.
Unexpectedly, FlnA-deficient platelets failed to respond 
normally to agonists for the ITAM- and ITAM-like–containing 
receptors GPVI or CLEC-2. In particular, the actin assembly 
reaction was blunted in response to rhodocytin (unpublished 
data) or CRP, but not thrombin. FlnA-null platelets also had 
decreased -granule secretion and integrin IIb3 activation. 
This diminished response is not a result of the lack of GPVI or 
CLEC-2, as FlnA-null platelets express normal or higher   
numbers of these receptors per cell (unpublished data). The 
possibility that FlnA-null platelets have general secretory and 
aggregatory defects was also eliminated because of their normal 
response to PMA, a direct activator of protein kinase C which 
bypasses ligation of platelet membrane receptors. Furthermore, 
IIb3 activation in response to the GPCR agonist ADP alone 
or in combination with the thromboxane analogue U46619 
and/or epinephrine was comparable between FlnA-null and 
WT platelets.
Platelets express at least three ITAM or ITAM-like– 
containing  receptors:  the  low  affinity  IgG  Fc  receptor 
FcRIIA, the collagen receptor GPVI–FcR chain complex, 
and CLEC-2. FcRIIA is expressed on human but not mouse 
platelets. After ligation of GPVI with collagen, CRP, or con-
vulxin, the two YXXL motifs of the associated FcR chain 
ITAM become phosphorylated by Src family kinases, i.e., Fyn 
and Lyn (Ezumi et al., 1998). Syk recognizes and binds the 
phosphorylated ITAM, leading to Syk autophosphoryla-
tion and activation (Poole et al., 1997). Downstream signals 
through adapter proteins, such as LAT and SLP-76, lead to 
PLC-2 phosphorylation and activation (Watson et al., 2005). 
Active PLC-2 hydrolyzes membrane bound polyphospho-
inositides, notably phosphatidylinositol 4,5-bisphosphate, to 
form soluble inositol 1,4,5-trisphosphate, which releases cyto-
solic calcium from the internal stores, and membrane-bound 
1,2-diacylglycerol, which activates protein kinase C. Sig-
nals are also sent to phosphoinositide 3-kinase, generating   
D3-containing polyphosphoinositides (Pasquet et al., 1999). 
CLEC-2 only contains a single YXXL motif but appears to be 
active as a dimer (Watson et al., 2009; Hughes et al., 2010) 
and signals through many of the same components as GPVI 
because platelets lacking LAT, SLP-76, or PLC-2 are not 
receptive to ligation of this receptor with rhodocytin (Suzuki-
Inoue et al., 2006; Fuller et al., 2007).
We traced the failure of FlnA-null platelets to respond nor-
mally to agonists for GPVI or CLEC-2 to decreased Syk phos-
phorylation, which then poorly activates downstream signaling 
effectors such as PLC-2. Furthermore, Syk appeared to be 
cytoplasmic in FlnA-null platelets stimulated through GPVI 
rather than membrane associated as in WT controls. Together, 
the data indicate that FlnA contributes to Syk spatial distribu-
tion to the cytoplasmic surface of the platelet plasma mem-
brane, a prerequisite for the docking to the ITAM or ITAM-like 
males that survived had a macrothrombocytopenia, with <15% 
of normal blood platelet count and 2.5-fold enlarged plate-
lets, but displayed no gross anatomical anomalies.
FlnA-null platelets had deleterious cytoskeletal alterations, 
resulting in inadequately cross-linked cytoplasmic actin fila-
ments and poor attachment of the filaments to the membrane. 
FlnB expression levels appeared to be increased in FlnA-null 
platelets, compared with WT, which is consistent with a re-
cently described compensatory FlnB expression increase in 
FlnA knockdown endothelial cells (Del Valle-Pérez et al., 
2010). FlnB concentration levels, however, may be compara-
ble in WT and FlnA-null platelets, relative to the increased 
volume and total protein content of FlnA-null platelets, com-
pared with WT controls. Nevertheless, although FlnB has the 
same binding site for the cytoplasmic tail of GPIb on repeat 
17 (Nakamura et al., 2006), it does not compensate for FlnA 
absence, and no GPIb was detected linked to F-actin in 
FlnA-null platelets. The F-actin/G-actin ratio at rest and the 
actin assembly reaction of FlnA-null platelets in response to 
thrombin were normal, as assessed by centrifugation of Triton 
X-100  platelet  lysates  and/or  intracellular  flow  cytometry. 
The data show that the F-actin disassembly/assembly steps in 
the activation reaction occur normally in FlnA-null platelets, 
as described for FlnA-null fibroblasts (Feng et al., 2006; Hart 
et al., 2006).
As predicted, biochemical experiments revealed that all   
of the VWF receptor GPIb was Triton X-100 soluble and, 
therefore, untethered to the actin cytoskeleton in FlnA-null 
platelets, resulting in a disorganized GPIb topology on the 
platelet surface. Together, the data show that FlnA is required 
for normal platelet morphology and circulation and confirm 
that the macrothrombocytopenia associated with Bernard-
Soulier syndrome results from the lack of the FlnA-GPIb 
linkage to the actin cytoskeleton (Ware et al., 2000; Kanaji   
et al., 2002). Low platelet counts and large platelets have 
been described in periventricular heterotopia female patients   
(Parrini et al., 2006). These patients were carriers with only 
one mutant allele and are expected to have two platelet pop-
ulations: one that is normal and one expressing mutant FlnA. 
FlnA+/ female mice have a mild thrombocytopenia with only 
5% of their circulating platelets being FlnA null and enlarged. 
Further studies are required to determine the distribution of 
circulating FlnA-deficient platelets in periventricular hetero-
topia patients.
FlnAloxP/y GATA1-Cre males had a more severe bleeding 
phenotype than their macrothrombocytopenia would predict, 
indicating  that  FlnA-null  platelets  have  functional  defects.   
Indeed, there was loss of GPVI and GPIb function in the ab-
sence of FlnA, as adhesion to collagen and collagen-associated 
VWF was diminished in FlnA-null platelets under flow condi-
tions. Whether FlnA influences the ligand binding properties 
of GPIb has been controversial in the literature. Some groups 
have reported that it enhances (Dong et al., 1997; Cranmer   
et al., 1999, 2005; Mistry et al., 2000; Williamson et al., 2002; 
Schade et al., 2003) and others that it diminishes (Englund et al., 
2001). Our studies directly confirm the former, pointing out 1976 FlnA regulates platelet signaling and function | Falet et al.
the protein tyrosine kinase Syk. FlnA interacts with Syk through 
its Ig repeat 5 and, thus, docks Syk near the plasma membrane 
where it can bind GPVI, CLEC-2, and possibly GPIb, initiat-
ing or reinforcing/amplifying their signaling cascades.
MATERIALS AND METHODS
Mice. FlnA+/ and FlnAloxP/loxP mice on a 129/Sv × C57BL/6 background 
were provided by Y. Feng and C. Walsh (Howard Hughes Medical Insti-
tute, Boston, MA; Feng et al., 2006). GATA1-Cre transgenic mice on a 
BALB/c background were provided by Y. Fujiwara and S.H. Orkin (Dana 
Farber Cancer Institute, Howard Hughes Medical Institute, Boston, MA; 
Jasinski  et  al.,  2001).  FlnAloxP/loxP  females  were  bred  with  homozygous 
GATA1-Cre  transgenic  males  to  excise  the  floxed  FLNA  allele  in  the   
erythroid/megakaryocytic lineage. Mice were treated as approved by the 
Children’s Hospital Animal Care and Use Committee.
Antibodies and reagents. Rabbit antibody directed against aa 1758–1767 
of  mouse  FlnA  (APQYNYPQGS)  was  produced  by  Invitrogen.  Rabbit 
anti-FlnA antibody 4762 was purchased from Cell Signaling Technology. 
Rabbit  anti-FlnB  antibody  and  mouse  anti-phosphotyrosine  antibody   
4G10 were purchased from Millipore. Mouse anti-phosphotyrosine antibody 
PY20 was obtained from BD. Rabbit anti-Syk antibody BR15 was supplied 
by M. Tomlinson (DNAX Research Institute, Palo Alto, CA). Control rab-
bit antibody, rabbit anti-Syk antibody N19, and rabbit anti–PLC-2 Q20 
were obtained from Santa Cruz Biotechnology, Inc. Antibodies directed 
against mouse GPIb (CD42b), GPIb (CD42c), GPIX (CD42a), GPV 
(CD42d), GPVI, and active IIb3 were obtained from Emfret Analytics. 
Antibodies directed against mouse P-selectin (CD62P) and GPIIIa (CD61 
and integrin 3) were obtained from BD. CM-Orange, Oregon green 488–
labeled fibrinogen, and Alexa Fluor 488–labeled donkey anti–mouse IgG 
and anti–rabbit IgG antibodies were obtained from Invitrogen. Protein G 
Sepharose and glutathione Sepharose beads were obtained from GE Health-
care. The CRP (amino acids GCO(GPP)10GCOG) was synthesized by the 
Tufts  University  Core  Facility  and  cross-linked  as  described  previously 
(Morton et al., 1995). Rhodocytin was purified from the venom of Callose-
lasma  rhodostoma  (Suzuki-Inoue  et  al.,  2006).  ADP  was  obtained  from 
Chrono-log and U46619 from Enzo Life Sciences. All other reagents were 
of the highest purity available (Sigma-Aldrich).
Complete blood count. Blood was collected from mice by retroorbital 
plexus bleeding in EDTA. Peripheral blood platelet count was performed 
using an ADVIA 120/2120 automated hematology analyzer (Bayer Health-
Care; Falet et al., 2009).
Bleeding time assay. Mouse tail bleeding times were determined by snip-
ping 5 mm of distal mouse tail and immediately immersing the tail in 37°C 
isotonic saline (Ware et al., 2000). A complete cessation of bleeding was de-
fined as the bleeding time. Measurements exceeding 10 min were stopped 
by cauterization of the tail. Data were statistically analyzed by the Kaplan-
Meier method (Kaplan and Meier, 1958).
Platelet preparation. Blood was collected from mice by retroorbital plexus 
bleeding and anticoagulated in ACD for experiments with washed platelets 
or in citrate for experiments with PRP. Mouse PRP was obtained by cen-
trifugation of the blood at 100 g for 8 min, followed by centrifugation of the 
supernatant and the buffy coat at 100 g for 6 min. Mouse platelets were iso-
lated by two sequential centrifugations of the PRP at 1,200 g for 5 min in 
140 mM NaCl, 5 mM KCl, 12 mM trisodium citrate, 10 mM glucose, and 
12.5 mM sucrose, pH 6.0 (washing buffer), and resuspended in 10 mM 
Hepes, 140 mM NaCl, 3 mM KCl, 0.5 mM MgCl2, 5 mM NaHCO3,   
and 10 mM glucose, pH 7.4 (resuspension buffer), as previously described 
(Hoffmeister et al., 2003). Platelet concentration was adjusted to 2–5 × 108/ml 
depending on the assay performed, and platelets were allowed to rest for   
30 min before use.
sequences of GPVI and CLEC-2 and phosphorylation of Syk. 
This is a surprising finding and one that posits FlnA as essential 
for the very early Syk dependent steps in ITAM and ITAM-
like based signaling.
Previous  observations  have  suggested  that  GPVI  and 
CLEC-2 must be coupled to the platelet cytoskeleton to func-
tion. CLEC-2 signaling is inhibited by cytochalasin d (Pollitt 
et al., 2010) and signaling of GPVI is greatly diminished by 
treating platelets with latrunculin A (unpublished data), an 
agent which depolymerizes actin filaments. The actin filament 
cross-linking activity of FlnA may be important for Syk re-
cruitment and activation by the two receptors. FlnA and Syk 
were associated in both resting and activated platelets. Direct 
binding was reconstituted using purified Syk and FlnA fusion 
proteins and was restricted to Ig repeat 5 of FlnA using a series 
of FlnA truncates. Binding to FlnA Ig repeat 5 is novel, as 
most FlnA interacting partners bind to the C-terminal region 
containing Ig repeats 16–24 (Stossel et al., 2001; Feng and 
Walsh, 2004; Zhou et al., 2010). Mutations in FlnA Ig repeat 
5 have been associated with familial cardiac valvular dystrophy 
(Kyndt et al., 2007). However, the consequence of these mu-
tations on platelet activation remains to be determined, as does 
the location of the binding interface on Syk.
Stable platelet adhesion and aggregate formation under ar-
terial shear condition, events which normally require activa-
tion of the IIb3 integrin downstream of GPVI ligation by 
collagen and that of GPIb by VWF, were severely impaired 
in the absence of FlnA (Ruggeri and Mendolicchio, 2007; 
Diener et al., 2009). Syk participates in the signaling cascade 
induced by GPIb ligation, particularly in the calcium rise and 
activation of PI-3 kinase which follow ligation, and is inti-
mately involved in downstream signaling to IIb3 (Asazuma 
et al., 1997; Yanabu et al., 1997; Falati et al., 1999; Ozaki et al., 
2005). It is likely that FlnA modulates Syk phosphorylation 
and activation downstream of GPIb ligation as well. Further 
experimental evidence is required to test this hypothesis.
Our data further show that P-selectin expression and fi-
brinogen binding, but not actin assembly, were attenuated in 
FlnA-null platelets stimulated with the GPCR agonist throm-
bin. This could be a result of the altered expression and loca-
tion of GPIb, such that it is less able to present thrombin to 
its GPCR PAR4. Another explanation is that signals origi-
nated from GPVI or IIb3 contribute to the thrombin sig-
naling cascade. Boylan et al. (2006) have reported that platelets 
that lost GPVI after in vivo injection of an anti-GPVI antibody 
had  diminished  functional  responses  to  thrombin  and  that   
outside-in signaling downstream of IIb3 engagement also 
uses an ITAM-based pathway (Boylan et al., 2008). Older stud-
ies have shown that Syk is phosphorylated and activated after 
platelet stimulation with thrombin (Taniguchi et al., 1993; 
Clark et al., 1994). Thus, it is also possible that FlnA plays a yet 
undefined scaffolding role in thrombin receptor signaling.
In conclusion, our results show that FlnA is not only re-
quired for platelet morphology and circulation but also for sig-
naling through platelet ITAM and ITAM-like containing 
receptors (i.e., GPVI and CLEC-2), which requires activation of JEM VOL. 207, August 30, 2010 
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Flow chamber studies. Blood was collected from mice by retroorbital 
plexus bleeding and anticoagulated in 40 µM PPACK and 20 µg/ml enoxa-
parin. PRP was separated by centrifugation at 80 g for 6 min and purified at 
180 g for 5 min for WT and at 80 g for 5 min for FlnA-null platelets, respec-
tively. Platelets were collected by centrifugation at 640 g for 6 min in the 
presence of 2 µg/ml prostacyclin and resuspended in modified Tyrode’s buf-
fer (140 mM NaCl, 0.36 mM Na2HPO4, 3 mM KCl, 12 mM NaHCO3,   
5 mM Hepes, and 10 mM glucose, pH 7.3) containing 0.2% BSA and la-
beled with 2.5 mg/ml calcein orange. Platelet-poor blood was reconstituted 
with labeled platelets and remaining plasma at 108/ml platelets. Using a 
0.0127-cm silicon rubber gasket, a parallel plate flow chamber (GlycoTech) 
was assembled onto 35-mm diameter round glass coverslips, which had been 
coated with 100 µg/ml collagen type I (Nycomed). Perfusion was performed 
at a shear rate of 1,500/s for 3 min. Platelet adhesion to collagen-associated 
plasma VWF was monitored with an Axiovert 135 inverted microscope 
(Carl Zeiss, Inc.) at 32× and a silicon-intensified tube camera C 2400 
(Hamamatsu Photonics) and analyzed with Image SXM 1.62 (National In-
stitutes of Health).
Statistical analysis. Statistical analysis was performed using the unpaired 
Student’s t test. A p-value <0.05 was considered statistically significant.
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